Download Ebook Free Significant Pharmaceuticals Reported In US Patents

Significant Pharmaceuticals Reported in US Patents

Author : Thomas F. DeRosa
Publisher : Elsevier
Release Date : 2010-07-07
Category : Science
Total pages :700
GET BOOK

Significant Pharmaceuticals Reported in US Patents identifies the next generation of pharmaceuticals reported in US Patents. This "hands-on" title provides explicit laboratory methods for preparing the most recent and effective medications. Each entry documents the biological testing protocols used to evaluate a drug and the significance of the current treatment agent over previous methods. Pharmaceuticals are included in this review only if at least two of the following criteria were met: Effectiveness in treating an illness, Innovative, ease of preparation, synergy with existing Medications. Pharmaceuticals are reported for 27 separate classes of illness, including: AIDS, Alzheimer's Disease, Cardiovascular Disorders, Diabetes, Epilepsy, Hepatitis C, Osteoporosis, Obesity and Sleep Disorders. Significant Pharmaceuticals Reported in US Patents has been designed to be used as both a reference and synthetic guide for pharmaceutical, medicinal and organic chemists and graduate students. Researchers working in other areas will also find the information valuable as in many instances intermediates or the next generation pharmaceutical are readily convertible into other industrial products including: anti-oxidants, chemical additives, herbicides, polymer precursors, water purification agents. Clear structural depictions of reagents and chemical transformations have been supplied to permit the identification of other future applications. Identifies next generation pharmaceuticals Provides practical preparation methods for each active agent and derivatives Documents the analytical characterization and biological testing results of active agents

Patent term extension and pharmaceutical innovation

Author : United States. Congress. House. Committee on Science and Technology. Subcommittee on Investigations and Oversight
Publisher : Unknown
Release Date : 1983
Category : Drugs
Total pages :293
GET BOOK

Patent-term Extension and the Pharmaceutical Industry

Author : Anonim
Publisher : Unknown
Release Date : 1981
Category : Drugs
Total pages :74
GET BOOK

Drug Price Competitition and Patent Term Restoration Act of 1984

Author : United States. Congress. Senate. Committee on Labor and Human Resources
Publisher : Unknown
Release Date : 1984
Category : Administrative procedure
Total pages :370
GET BOOK

Journal of the American Pharmaceutical Association

Author : American Pharmaceutical Association
Publisher : Unknown
Release Date : 1922
Category : Drugs
Total pages :129
GET BOOK

PAREXEL's Pharmaceutical R&D Statistical Sourcebook

Author : Anonim
Publisher : Unknown
Release Date : 2001
Category : Drugs
Total pages :129
GET BOOK

C and D

Author : Anonim
Publisher : Unknown
Release Date : 1893
Category : Pharmaceutical industry
Total pages :129
GET BOOK

Bulletin of Pharmacy

Author : Anonim
Publisher : Unknown
Release Date : 1891
Category :
Total pages :129
GET BOOK

Pharmaceutical Journal;

Author : Anonim
Publisher : Unknown
Release Date : 1884
Category : Pharmacy
Total pages :129
GET BOOK

Reports of Patent, Design, and Trade Mark Cases

Author : Anonim
Publisher : Unknown
Release Date : 1974
Category : Design protection
Total pages :129
GET BOOK

Daily Report, East Asia

Author : Anonim
Publisher : Unknown
Release Date : 1996
Category : Asia
Total pages :129
GET BOOK

Representational Fairness in WTO Rule-making

Author : Mohamed Omar Gad
Publisher : British Inst of International & Comparative
Release Date : 2006
Category : Law
Total pages :333
GET BOOK

This book examines representational fairness in WTO rule making. The context of examination is the pharmaceutical-related provisions of the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement and the interests of developing countries and pharmaceutical multinational enterprises therein. The book analyzes the negotiation and implementation periods of the specified TRIPS provisions and the legal disputes that arose, covering the period from the mid-1980s, until the adoption of the Doha Declaration on the TRIPS Agreement and Public Health in November 2001. An imbalance reflected in the negotiated text in favor of pharmaceutical MNEs' interests during the negotiation process is characterized as 'top-down' rule making. Reacting to this, developing countries exerted pressure from the 'bottom-up' hindering the implementation of these TRIPS provisions. This retorting action, while instilling a degree of balance, congests the TRIPS regime and the larger WTO system with additional dispute proceedings leading to strains in North-South relations. The volume concludes with selective suggestions focusing on the rule making process of the WTO and proposes measures to reduce the likelihood of a deficiency in representational fairness occurring in future negotiations.